Zobrazeno 1 - 10
of 187
pro vyhledávání: ''
Autor:
Yves Dauvilliers, Johan Verbraecken, Markku Partinen, Jan Hedner, Tarja Saaresranta, Ognian Georgiev, Rumen Tiholov, Isabelle Lecomte, Renaud Tamisier, Patrick Lévy, Catherine Scart-Gres, Jeanne-Marie Lecomte, Jean-Charles Schwartz, Jean-Louis Pépin, Valerie Attali, Patrice Bourgin, Frederic Gagnadoux, Farhad Baharloo, Soren Berg, Olli Polo, Jan Anders Hedner, Yeksel Peker, Alexander Blau, Diego Garcia Borreguero, Francisco Javier Puertas Cuesta, Georgi Belev, Yavor Ivanov, Hristo Metev, Diana Petkova, Dejan Dokic, Merita Ismajli Marku, Biserka Jokovska Kaeva, Slavko Jankovic, Ivan Kopitovic, Miodrag Vukcevic
Publikováno v:
American Journal of Respiratory and Critical Care Medicine
American Journal of Respiratory and Critical Care Medicine, American Thoracic Society, 2020, 201 (9), pp.1135-1145. ⟨10.1164/rccm.201907-1284OC⟩
American journal of respiratory and critical care medicine
American Journal of Respiratory and Critical Care Medicine, American Thoracic Society, 2020, 201 (9), pp.1135-1145. ⟨10.1164/rccm.201907-1284OC⟩
American journal of respiratory and critical care medicine
International audience; Rationale: Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome.Objectives: To evaluate the efficacy and safety of pitolisant, a selective histamine H3 receptor antagonist with wake-pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75002b482574fd4cdea4dfe2b7ebf2c4
https://hal.umontpellier.fr/hal-03414861
https://hal.umontpellier.fr/hal-03414861
Autor:
Nazzareno Galiè, Ioana R. Preston, Marius M. Hoeper, Lilla Di Scala, Lewis J. Rubin, G. Simonneau, Vallerie V. McLaughlin, Sean Gaine, Harrison W. Farber, Olivier Sitbon, Kelly Chin, Richard N. Channick, R Preiss, Victor F. Tapson, Irene M. Lang, Hossein Ardeschir Ghofrani
Publikováno v:
The Journal of Heart and Lung Transplantation. 37:401-408
Background: Parenteral prostacyclin analogs that target the prostacyclin pathway have been used to treat pulmonary arterial hypertension (PAH) since the 1990s. Abrupt discontinuation of parenteral prostacyclin analogs can be associated with acute det
Autor:
Julie C. Yates, Jørgen Vestbo, Robert D. Brook, Natacha Gallot, Robert A. Wise, Peter M.A. Calverley, Fernando J. Martinez, David E. Newby, Bartolome R. Celli, Sally Kilbride, Julie A. Anderson, Courtney Crim
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 197:47-55
Rationale: Many patients with chronic obstructive pulmonary disease (COPD) have an accelerated loss of lung function. It is unclear whether drug treatment can modify this in patients with moderately severe disease.Objectives: In a prespecified analys
Publikováno v:
Pulmonary Therapy
Introduction Comparative data on the efficacies of long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) combinations for the treatment of moderate-to-very-severe chronic obstructive pulmonary disease (COPD) are limited. The aim
Autor:
Courtney Crim, Nicholas J. Cowans, Robert D. Brook, Peter M.A. Calverley, Dennis E. Niewoehner, Julie C. Yates, Jørgen Vestbo, Julie A. Anderson, Bartolome R. Celli, David E. Newby, Mark T. Dransfield, Sally Kilbride, Fernando J. Martinez
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 195:881-888
Inhaled corticosteroids have been shown to decrease exacerbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Their effects in patients with milder airflow obstruction remain unclear.This was an analysis of exace
Autor:
Leif Bjermer, Sivan Weiss, Catherine Lemière, Jorge Maspero, Matthew Germinaro, James Zangrilli
Publikováno v:
Chest. 150(4):789-798
Background This phase 3 study further characterizes the efficacy and safety of reslizumab (a humanized anti-IL-5 monoclonal antibody) in patients aged 12 to 75 years with asthma inadequately controlled by at least a medium-dose inhaled corticosteroid
Publikováno v:
Pulmonary Therapy. 2:91-114
An integrated analysis was performed using safety data from 18 randomized, parallel-group studies from the fluticasone furoate/vilanterol (FF/VI) GSK asthma clinical study program. Efficacy data from four pivotal studies were also analyzed. Data were
Autor:
Dawn Midwinter, Neil Barnes, Steffen E. Petersen, Ian S Stone, Leonette John, Redha Boubertakh, Richard Follows, Wai-Yee James
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 193:717-726
Patients with chronic obstructive pulmonary disease develop increased cardiovascular morbidity with structural alterations.To investigate through a double-blind, placebo-controlled, crossover study the effect of lung deflation on cardiovascular struc
Autor:
Gisela Meyer, Robert Naeije, Victor F. Tapson, Milton Packer, Marius M. Hoeper, Rogério Souza, Hikmet Al Hiti, Hossein Ardeschir Ghofrani, Jonathan Tolson, Richard N. Channick, Vallerie V. McLaughlin, Jean Christophe Lemarié
Publikováno v:
European Respiratory Journal. 46:405-413
The safety and efficacy of adding bosentan to sildenafil in pulmonary arterial hypertension (PAH) patients was investigated.In this prospective, double-blind, event-driven trial, symptomatic PAH patients receiving stable sildenafil (≥20 mg three ti
Autor:
Ulrich Bothner, Lorcan McGarvey, Gary T. Ferguson, Alan Hamilton, Sheldon Magder, Kay Tetzlaff, Claus Vogelmeier, Dennis E. Niewoehner, Paul Sachs, Andrea Koch, Lawrence Korducki
Publikováno v:
COPD
McGarvey, L, Niewoehner, D, Magder, S, Sachs, P, Tetzlaff, K, Hamilton, A, Korducki, L, Bothner, U, Vogelmeier, C, Koch, A & Ferguson, G T 2015, ' One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis ', COPD: Journal of Chronic Obstructive Pulmonary Disease, vol. 12, no. 5, pp. 484-493 . https://doi.org/10.3109/15412555.2014.991864
McGarvey, L, Niewoehner, D, Magder, S, Sachs, P, Tetzlaff, K, Hamilton, A, Korducki, L, Bothner, U, Vogelmeier, C, Koch, A & Ferguson, G T 2015, ' One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis ', COPD: Journal of Chronic Obstructive Pulmonary Disease, vol. 12, no. 5, pp. 484-493 . https://doi.org/10.3109/15412555.2014.991864
The novel long-acting β2-agonist olodaterol demonstrated an acceptable safety profile in short-term phase II clinical studies. This analysis of four randomized, double-blind, placebo-controlled, parallel-group, phase III studies (1222.11, NCT0078221